These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. A genomic case study of mixed fibrolamellar hepatocellular carcinoma. Griffith OL; Griffith M; Krysiak K; Magrini V; Ramu A; Skidmore ZL; Kunisaki J; Austin R; McGrath S; Zhang J; Demeter R; Graves T; Eldred JM; Walker J; Larson DE; Maher CA; Lin Y; Chapman W; Mahadevan A; Miksad R; Nasser I; Hanto DW; Mardis ER Ann Oncol; 2016 Jun; 27(6):1148-1154. PubMed ID: 27029710 [TBL] [Abstract][Full Text] [Related]
11. DNAJB1-PRKACA fusions occur in oncocytic pancreatic and biliary neoplasms and are not specific for fibrolamellar hepatocellular carcinoma. Vyas M; Hechtman JF; Zhang Y; Benayed R; Yavas A; Askan G; Shia J; Klimstra DS; Basturk O Mod Pathol; 2020 Apr; 33(4):648-656. PubMed ID: 31676785 [TBL] [Abstract][Full Text] [Related]
12. Novel protein kinase cAMP-Activated Catalytic Subunit Alpha (PRKACA) inhibitor shows anti-tumor activity in a fibrolamellar hepatocellular carcinoma model. Toyota A; Goto M; Miyamoto M; Nagashima Y; Iwasaki S; Komatsu T; Momose T; Yoshida K; Tsukada T; Matsufuji T; Ohno A; Suzuki M; Ubukata O; Kaneta Y Biochem Biophys Res Commun; 2022 Sep; 621():157-161. PubMed ID: 35839742 [TBL] [Abstract][Full Text] [Related]
13. GalNAc-conjugated siRNA targeting the DNAJB1-PRKACA fusion junction in fibrolamellar hepatocellular carcinoma. Neumayer C; Ng D; Requena D; Jiang CS; Qureshi A; Vaughan R; Prakash TP; Revenko A; Simon SM Mol Ther; 2024 Jan; 32(1):140-151. PubMed ID: 37980543 [TBL] [Abstract][Full Text] [Related]
14. DNAJB1-PRKACA-positive metastatic fibrolamellar carcinoma with unknown primary in a pediatric patient. Balbeur S; Dumortier A; Mergen J; Libbrecht L; Torbenson M; Boulanger C; de Ville de Goyet M; Van Damme A; Brichard B Pediatr Blood Cancer; 2020 Feb; 67(2):e28060. PubMed ID: 31736218 [TBL] [Abstract][Full Text] [Related]
15. The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma. Bauer J; Köhler N; Maringer Y; Bucher P; Bilich T; Zwick M; Dicks S; Nelde A; Dubbelaar M; Scheid J; Wacker M; Heitmann JS; Schroeder S; Rieth J; Denk M; Richter M; Klein R; Bonzheim I; Luibrand J; Holzer U; Ebinger M; Brecht IB; Bitzer M; Boerries M; Feucht J; Salih HR; Rammensee HG; Hailfinger S; Walz JS Nat Commun; 2022 Oct; 13(1):6401. PubMed ID: 36302754 [TBL] [Abstract][Full Text] [Related]
17. Oncogenic Addiction of Fibrolamellar Hepatocellular Carcinoma to the Fusion Kinase DNAJB1-PRKACA. Neumayer C; Ng D; Jiang CS; Qureshi A; Lalazar G; Vaughan R; Simon SM Clin Cancer Res; 2023 Jan; 29(1):271-278. PubMed ID: 36302174 [TBL] [Abstract][Full Text] [Related]
18. Conformational Landscape of the PRKACA-DNAJB1 Chimeric Kinase, the Driver for Fibrolamellar Hepatocellular Carcinoma. Tomasini MD; Wang Y; Karamafrooz A; Li G; Beuming T; Gao J; Taylor SS; Veglia G; Simon SM Sci Rep; 2018 Jan; 8(1):720. PubMed ID: 29335433 [TBL] [Abstract][Full Text] [Related]
19. Integrated Phosphoproteomics for Identifying Substrates of Human Protein Kinase A ( Karamafrooz A; Brennan J; Thomas DD; Parker LL J Proteome Res; 2021 Oct; 20(10):4815-4830. PubMed ID: 34436901 [TBL] [Abstract][Full Text] [Related]
20. Fibrolamellar carcinoma in the Carney complex: PRKAR1A loss instead of the classic DNAJB1-PRKACA fusion. Graham RP; Lackner C; Terracciano L; González-Cantú Y; Maleszewski JJ; Greipp PT; Simon SM; Torbenson MS Hepatology; 2018 Oct; 68(4):1441-1447. PubMed ID: 29222914 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]